Patient Response to Immunotherapy Using Spliceosome Mutational Markers (PRISMM) | Johns Hopkins Kimmel Cancer Center

PRISMM is a Hopkins trial for patients with advanced cancer whose tumors have been sequenced. Your participation may help you – while you help us study and treat cancers with rare mutations.

Read the full article here

Related Articles